A study to assess NTproCNP as a new potential biomarker of atheroma risk and/or severity through clinical studies of blood samples from donors starting statin drug therapy including healthy donors and those with overt coronary artery disease.

Christchurch Heart Institute0 个研究点目标入组 65 人开始时间: 2013年5月13日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Group 1; Males aged 20-25y. No family history (1st and 2nd degree relatives) of coronary artery disease (CAD), stroke or peripheral vascular disease (PVD). No personal history of high BP, smoking, diabetes, lipid disorders or renal disease. BMI between 18-25. Normal BP (<140 systolic, <90 diastolic). Normal Blood lipid profile.
•Group 2; Males aged 40-60y. No family history (1st and 2nd degree relatives) of CAD, stroke or PVD. No personal history of high BP, smoking, diabetes, lipid disorders or renal disease. BMI between 18-25. Normal BP (<140 systolic, <90 diastolic). Normal Blood lipid profile.
•Group 3; Males diagnosed with overt coronary artery disease aged 40-60y about to start statin therapy. Allow family history of CAD, stroke or PVD. Allow personal history of high BP, lipid disorder.

•Unwilling or unable to give informed consent.
•Groups 1 & 2; On medication. BMI > 25. Systolic BP >140, Diastolic BP >90. Triglycerides >1.7mmol/L.
•Group 3; Subjects who have previously taken statin medication. Subjects with past episodes of heart failure, diabetics receiving insulin, raised plasma creatinine (> 110umol/L) and metabolic bone disease or recent fracture.

发起方

Christchurch Heart Institute